13 min listen
Eyes on the prize: Novo buys Catalent
FromBioSpace
ratings:
Length:
29 minutes
Released:
Feb 14, 2024
Format:
Podcast episode
Description
This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufacturing contracts, customers and consequences with regulators; as well as discussion around the ongoing issues with drug shortages and manufacturing challenges and whether it the move will help accelerate manufacturing for Wegovy and Ozempic.
Plus, what's next for Alzheimer's treatment following Biogen's withdrawal of Aduhelm?
As mentioned in this episode: you can subscribe to ClinicaSpace for our latest special edition on Leqembi.
Plus, what's next for Alzheimer's treatment following Biogen's withdrawal of Aduhelm?
As mentioned in this episode: you can subscribe to ClinicaSpace for our latest special edition on Leqembi.
Released:
Feb 14, 2024
Format:
Podcast episode
Titles in the series (45)
First ever CRISPR gene therapy approval: What happens next? by BioSpace